– Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors – Qfitlia is the sixth Alnylam-discovered ...

RNA interference (RNAi) technology has gradually become a cutting-edge technology for treating diseases such as genetic disorders and cancer due to its huge potential in gene expression regulation.

Gene knockdown is a common method for studying gene function by reducing messenger ribonucleic acid (mRNA) levels without altering the deoxyribonucleic acid (DNA). Among the available techniques, RNA ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...

In everyday life, when things turn out the opposite of what you expect, it's usually cause for frustration. In science, it's often the starting point for discovery. That's what happened to a team of ...

REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has ...